Valued at $81.0M at its seed round, Jul 2025. Nothing has traded since.
- ·Watch ADvantage Therapeutics: the Monday email on marks, rounds and moves
Valuation timeline
0 priced rounds · 21 daily marks since · Sep 2026 – Oct 2026Funding history
3 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Jun 2023 | Early Stage VC | $13.7M | ▮ | ▮ |
| May 2022 | Seed Round | $275K | ▮ | ▮ |
| Jun 2021 | Early Stage VC | $5.0M | ▮ | ▮ |
How ADvantage Therapeutics's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For ADvantage Therapeutics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →
Frequently asked
- What is ADvantage Therapeutics worth?
- ADvantage Therapeutics is valued at $81.0M as of Oct 2026. Valued at $81.0M at its seed round, Jul 2025. Nothing has traded since.
- How much has ADvantage Therapeutics raised?
- ADvantage Therapeutics has raised $18.7M in total funding across 3 recorded rounds.
- When did ADvantage Therapeutics last raise?
- ADvantage Therapeutics last raised in Jun 2023 (Early Stage VC), raising $13.7M.